Hepali

RMA

藥業集

the People

tock Code:

ODIUM I
ROVAL F

Shenzhen Hepa
sidiaries referred t
of Securities on Th
g of Stocks on Shenzh

the Company (the "**Bo**
Co., Ltd. ("**Shen hen Te**
ed that, the U.S. Food and
lier of the finish dose medi
noxaparin sodium injection (s
pharmaceutical industry, and

THE DRUG

e: Enoxaparin Sodium Inje

ons: Prophylaxis of venous th
bosis), especially thrombosis relate
eveloped deep vein embolism with
bolism with light clinical syndromes, exc
hrombolytic therapies; treatment of unstable
combination with aspirin; and used in hemo
thrombosis

onary
g surgeries or
ocardial infarction in
poreal circulation to prevent

(III) Dosage form: Injection

(IV) Strength: 100 mg/mL (30mg/0.3
.4mL, 60mg/0.6mL, 80mg/0.8mL); 150 mg/mL (120mg/0.8mL)

(V) Registration category: Generic drug

(VI) Supplementary approval content: Addition of the supplier of drugs and active pharmaceutical ingredients under the original marketing approval, namely Shenzhen Techdow

BENEFITS AND IMPACTS TO THE COMPANY

Currently, Inhixa, Neoparin and Prolongin, the three enoxaparin sodium injection brands of the Group, have been approved in a total of 35 countries and sold in 21 countries. Meanwhile, the Group also can supply enoxaparin sodium injection to its customers in 15 other countries, including the United States. This approval is also the first time that Shenzhen Techdow's DMF (Drug Master File) for enoxaparin sodium active pharmaceutical ingredients has been approved by the FDA for activation in the United States.

The United States is a major and growing market for the sales of enoxaparin sodium injections. According to the Frost & Sullivan report, the sales of finished dose enoxaparin sodium pharmaceutical products in the United States amounted to approximately US$455 million in 2019, accounting for approximately 17% of the global market sales. The United States market is expected to grow at a CAGR of 10.7% to reach US$838 million in 2025.

In the first half of 2020, the Group's global sales of enoxaparin sodium injection was increased by 37%, with unaudited sales revenue of RMB631.3 million. The Group is currently the sole supplier of enoxaparin sodium injection to the strategic partner that holds the marketing license in the United States; and the partner is responsible for all sales and distribution related expenses. The approval of this registration marks the beginning for the Group's finished dose pharmaceutical products entering the market in the United States. The Group expects to achieve sales by the end of this year. The future growth of finished dose pharmaceutical products business in the United States will further consolidate the Group's global business layout.

Announcement is hereby given.

By order of the Board
Shen hen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, PRC
September 21, 2020

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Sun Xuan; the non-executive director of the Company is Mr. Bu Haihua; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.